Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 73
Filtrar
2.
Langenbecks Arch Surg ; 408(1): 293, 2023 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-37526748

RESUMO

OBJECTIVE: To assess the effect of high inferior mesenteric artery tie on defecatory, urinary, and sexual function after surgery for sigmoid colon cancer. Performing a sigmoidectomy poses a notable risk of causing injury to the preaortic sympathetic nerves during the high ligation of the inferior mesenteric artery, as well as to the superior hypogastric plexus during dissection at the level of the sacral promontory. Postoperative defecatory and genitourinary dysfunction after sigmoid colon resection are often underestimated and underreported. METHODS: This study is a secondary research of a multicenter, single-blind, randomized clinical trial. The trial involved patients with sigmoid cancer who underwent either extended complete mesocolic excision (e-CME) or standard CME (s-CME). Patients completed questionnaires to assess defecatory, urinary, and sexual function before, 1 month after surgery, and 1 year after surgery. Multivariate analysis was conducted to identify factors associated with functional dysfunction. RESULTS: Seventy-nine patients completed functional assessments before and 1 year after surgery. One year after sigmoidectomy with a high tie of the inferior mesenteric artery, 15.2% of patients had minor low anterior resection syndrome (LARS) and 12.7% had major LARS; 22.2% of males and 29.4% of females had urinary dysfunction; and 43.8% of males and 27.3% of females had sexual dysfunction. After multivariate analysis, no significant associations were found between clinical and surgical factors and gastrointestinal or urinary dysfunction after 1 year of surgery. Age was identified as the only factor linked to sexual dysfunction in both sexes (women, ß = - 0.54, p = 0.002; men ß = - 0.38, p = 0.010). Regarding recovery outcomes, diabetes mellitus was identified as a contributing factor to suboptimal gastrointestinal recovery (p = 0.033) and urinary recovery in women (p = 0.039). Furthermore, the treatment arm was found to be significantly associated with the recovery of erectile function after 1 year of surgery (p = 0.046). CONCLUSIONS: A high tie of the inferior mesenteric artery during sigmoidectomy is associated with a high incidence of defecatory and genitourinary dysfunction. Age was identified as a significant factor associated with sexual dysfunction 1 year after sigmoid colon resection in both sexes. TRIAL REGISTRATION: Clinical trials NCT03083951 HIGHLIGHTS: • One year after high-tie sigmoidectomy, 27.9% of patients had LARS; 22.2% of the men and 29.4% of the women had urinary dysfunction; and 43.8% of the men and 27.3% of the women had sexual dysfunction. • e-CME is associated with a high rate of urinary dysfunction in men 1 year after surgery. However, after multivariate analysis, no association was found between e-CME and urinary dysfunction in men. • Age was correlated with the recovery of sexual function in both sexes 1 year after surgery. Furthermore, diabetes mellitus was identified as the factor associated with poorer recovery of urinary function in females.


Assuntos
Laparoscopia , Mesocolo , Neoplasias Retais , Masculino , Humanos , Feminino , Colo Sigmoide/cirurgia , Mesocolo/cirurgia , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/cirurgia , Neoplasias Retais/cirurgia , Método Simples-Cego , Colectomia/efeitos adversos
3.
Colorectal Dis ; 25(8): 1572-1577, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37400967

RESUMO

AIM: The aim of this work was to evaluate the robustness of randomized controlled trials (RCTs) on anal fistula management using the news tools of Fragility Index (FI), Reverse Fragility Index (RFI) and their corresponding fragility quotients. METHOD: A systematic search was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines which utilized MEDLINE, EMBASE, Cochrane Library and Web of Science databases. Inclusion criteria included RCTs related to the management of anal fistula published from 2000 to 2022 with dichotomous outcomes measures and 1:1 allocation. Calculation of FI and RFI was performed by creating 2 × 2 contingency tables by successively changing one nonevent to an event for each outcome measure until the result was made nonsignificant or significant, respectively. The Fragility Quotients were calculated by dividing the FI or RFI by the total sample size. Fragile results were defined as those with a FI or RFI equal to or less than the number of patients lost to follow-up. Additionally, those with a FI or RFI less than 3 were also considered fragile. Studies were considered extremely fragile if FI was ≤1 or FQ was ≤0.01. RESULTS: There were 36 RCTs that met our criteria, with 3223 patients. Among these, 19 (53%) were positive RCTs (p < 0.005) and 17 (47%) were negative RCTs (p > 0.05). The median FI was 2 (0-5). The analysis by categorical subgroup showed a strong correlation between FI and the p-value (p = 0.000) and the number of events (p = 0.011). The median RFI was 5 (3.5-9.5) and the subgroup analysis showed a strong correlation between RFI and the p-value (p = 0.000), sample size (0.021) and number needed to treat/number needed to harm (0.000). We considered 63.2% of positive RCTs to be fragile and 35.3% of negative RCTs. CONCLUSIONS: In the present study we demonstrated the lack of robustness of study findings in published RCTs in the field of anal fistula.


Assuntos
Fístula Retal , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Tamanho da Amostra , Bases de Dados Factuais , Fístula Retal/cirurgia
4.
BMC Surg ; 23(1): 9, 2023 Jan 13.
Artigo em Inglês | MEDLINE | ID: mdl-36639756

RESUMO

BACKGROUND: Subcuticular suture has proven to reduce superficial incisional SSI (si-SSI) in clean surgery. However, question remains regarding clean-contaminated procedures. The aim of this study is to assess if subcuticular suture is superior to staples in reducing si-SSI incidence in elective HBP surgery. METHODS: Single-centre, open-label, parallel, pragmatic randomized clinical trial conducted at a referral tertiary Hospital between January 2020 and April 2022. Patients eligible for elective HBP surgery were randomly assigned (1:1) to subcuticular suture or surgical staples wound closure using a minimisation method based on previously confirmed risk factors. The primary endpoint was the incidence of si-SSI. Considered secondary endpoints were major postoperative morbidity in both groups, additional wound complications, median hospital length of stay and need for re-hospitalisation. RESULTS: Of the 379 patients, 346 patients were randomly assigned to receive skin closure with staples (n = 173) or subcuticular suture (n = 173). After further exclusion of 11 participants, 167 and 168 patients, respectively in the control and the experimental group received their allocated intervention. For the primary endpoint, no significant differences in si-SSI rate were found: 17 (9.82%) staples group vs. 8 (4.62%) in subcuticular suture group (p = 0.062). Subset analysis confirmed absence of significant differences. As for secondary endpoints, overall wound complications did not differ significantly between two procedures: 19 (10.98%) vs. 10 (6.35%) (p = 0.127). There were no treatment related adverse events. However, occurrence of si-SSI contributed to major postoperative morbidity in both groups (p < 0.001 and p = 0.018) and to a substantially prolonged postoperative hospitalization (p = 0.015). CONCLUSIONS: Subcuticular suture might offer a relative benefit for skin closure reducing incidence of si-SSI after elective HBP surgery, although this was found not to be clinically relevant. Yet, this should not be interpreted as equivalence among both treatments. Therefore, wound closure strategy should not be based only on these grounds. TRIAL REGISTRATION NUMBER: ISRCTN Registry number ISRCTN37315612 (registration date: 14/01/2020).


Assuntos
Procedimentos Cirúrgicos do Sistema Digestório , Técnicas de Sutura , Humanos , Técnicas de Sutura/efeitos adversos , Procedimentos Cirúrgicos do Sistema Digestório/efeitos adversos , Grampeamento Cirúrgico , Infecção da Ferida Cirúrgica/epidemiologia , Infecção da Ferida Cirúrgica/prevenção & controle , Infecção da Ferida Cirúrgica/etiologia , Suturas/efeitos adversos
5.
Cir. Esp. (Ed. impr.) ; 100(11): 709-717, nov. 2022. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-212473

RESUMO

Objetivos: La mayoría de los ensayos clínicos realizados sobre pacientes con cáncer escamoso anal (CEA) excluyen pacientes inmunodeprimidos. El objetivo del presente estudio es comparar las características y los resultados oncológicos entre pacientes con CEA inmunocomprometidos e inmunocompetentes. Métodos: Estudio multicéntrico comparativo retrospectivo que incluye 2 cohortes consecutivas de pacientes, inmunocomprometidos e inmunocompetentes, diagnosticados de carcinoma escamoso anal. Se han investigado las características de los pacientes, los tratamientos realizados, la respuesta clínica al tratamiento con quimiorradioterapia (QRT), la recidiva local o a distancia, la supervivencia global (SG) y la supervivencia libre de enfermedad (SLE). Resultados: De enero 2012 a diciembre 2017 hemos estudiado a 84 pacientes, 47 (55,6%) mujeres, afectos de CEA, de los cuales 22 (26%) han sido pacientes inmunocomprometidos y 62 (74%) inmunocompetentes. Los pacientes inmunocomprometidos fueron más jóvenes (53 vs. 61 años; p=0,001), con un menor tamaño tumoral (p=0,044), y presentaban un mayor consumo de tabaco (p=0,034) y de drogas de uso parenteral (p=0,001). No se objetivaron diferencias significativas en los tratamientos administrados (p=0,301), tampoco difirió la respuesta clínica a la QRT (83 vs. 100%). Tampoco se observaron diferencias significativas en la supervivencia global (60 vs. 64%; p=0,756) o en la supervivencia libre de enfermedad a 5 años (SLE) (65 vs. 68%; p=0,338). Conclusiones: En el presente estudio no se observaron diferencias significativas en relación con los resultados oncológicos a largo plazo entre pacientes inmunocompetentes e inmunocomprometidos diagnosticados de CEA, con un grado de cumplimiento del tratamiento similar. Esta evidencia podría deberse al estrecho seguimiento y buen control terapéutico de pacientes infectados por HIV. (AU)


Objective: Most evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma. Method: Multicentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS). Results: A total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse.including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed. Conclusion: The present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients. (AU)


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Idoso , Carcinoma de Células Escamosas , Canal Anal , Hospedeiro Imunocomprometido , Estudos Retrospectivos , Análise de Sobrevida
6.
Rev. cir. (Impr.) ; 74(4): 368-375, ago. 2022. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-1407938

RESUMO

Resumen Objetivos: El sistema linfático del estómago es complejo y multidireccional, siendo difícil predecir el patrón de diseminación linfática en el adenocarcinoma (ADC) gástrico. Los objetivos de este trabajo son determinar si el analizar los grupos ganglionares de la pieza quirúrgica por separado tiene implicaciones en el estadiaje, además estudiar la afectación de diferentes grupos ganglionares. Materials y Método: Estudio observacional retrospectivo de pacientes intervenidos de gastrectomía y linfadenectomía con intención curativa por ADC en un hospital de referencia (2017-2021).,_Se han comparado aquellos pacientes cuya pieza quirúrgica se estudió en su totalidad (grupo A) con aquellos en los que se separaron los grupos ganglionares para su análisis (grupo B). En el grupo B, se ha analizado la afectación ganglionar de diferentes grupos ganglionares en base a la localización tumoral y el estadio pT. Resultados: Se incluyeron 150 pacientes. La media de ganglios analizados fue significativamente mayor cuando se separaron los grupos ganglionares (grupo B) (24,01 respecto a 20,49). La afectación ganglionar fue del 45,8%, 58,3% y 55,5% en los tumores de tercio superior, medio e inferior respectivamente, y los grupos difirieron en base a la localización tumoral. El riesgo de afectación ganglionar fue significativamente mayor y hubo más grupos ganglionares perigástricos afectos cuanto mayor era el estadio pT. Conclusiones: Separar los grupos ganglionares previo a su análisis aumenta el número de ganglios analizados mejorando el estadiaje ganglionar. Existen diferentes rutas de drenaje linfático dependiendo de la localización tumoral y la afectación ganglionar aumenta de forma paralela al estadio pT.


Objectives: The lymphatic system of the stomach is complex and multidirectional, making it difficult to predict the pattern of lymphatic spread in gastric adenocarcinoma (GAC). The aim of this paper is to determine if analyzing the lymph node groups of the surgical specimen separately has implications in the pathological staging, as well as to study the involvement rate of different lymph node groups. Material and Method: Retrospective observational study of patients who underwent curative intent gastrectomy and lymphadenectomy for GAC in a reference hospital (2017-2021). Those patients whose surgical specimen was studied as a whole (group A) were compared with those in whom the lymph node groups were separated by surgeons before analysis (group B). In group B, the involvement of different lymph node groups was analyzed based on tumor location and pT stage. Results: 150 patients were included. The mean number of lymph nodes analyzed was significantly higher when the lymph node groups were separately analyzed (group B) (24.01 compared to 20.49). Lymph node involvement was 45.8%, 58.3%, and 55.5% in tumors of the upper, middle, and lower third, respectively, and the involved groups differed depending on the tumor location. The higher the pT stage was, the risk of lymph node involvement was significantly higher and there were more perigastric lymph node groups affected. Conclusions: Separating lymph node groups prior to their analysis increases the number of lymph nodes analyzed and therefore improves lymph node staging. There are different lymphatic drainage routes depending on the tumor location and lymph node involvement increases in parallel with the pT stage.


Assuntos
Humanos , Masculino , Idoso , Neoplasias Gástricas/cirurgia , Adenocarcinoma/cirurgia , Estudos Retrospectivos , Excisão de Linfonodo/métodos , Linfonodos/patologia , Metástase Linfática/patologia , Invasividade Neoplásica/patologia , Estadiamento de Neoplasias
7.
Cir Esp (Engl Ed) ; 100(11): 709-717, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35850478

RESUMO

OBJECTIVE: Most evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma. METHOD: Multicentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS). RESULTS: A total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P = 0.001), with smaller tumoral size (P = 0.044) and reported higher rates of substance abuse including tobacco use (P = 0.034) and parenteral drug consumption (P = 0.001). No differences were found in administered therapies (P = 301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P = 0.756) and DFS (65 vs. 68%; P = 0.338) were observed. CONCLUSION: The present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients.


Assuntos
Neoplasias do Ânus , Carcinoma de Células Escamosas , Humanos , Feminino , Masculino , Estudos Retrospectivos , Neoplasias do Ânus/terapia , Neoplasias do Ânus/patologia , Carcinoma de Células Escamosas/terapia , Quimiorradioterapia/métodos , Hospedeiro Imunocomprometido
10.
Cir. Esp. (Ed. impr.) ; 99(9): 648-654, nov. 2021. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-218490

RESUMO

Introducción: La obesidad y la rápida pérdida de peso tras la cirugía bariátrica (CB) son factores de riesgo para la formación de colelitiasis. El objetivo de este trabajo es conocer la incidencia de colelitiasis de novo sintomática (CLNS) tras CB y analizar los factores de riesgo para su desarrollo. Métodos: Estudio observacional retrospectivo unicéntrico de los pacientes sometidos a CB entre enero de 2010 y diciembre de 2017. Se ha estudiado la incidencia de CLNS y se han analizado el género, la edad, las comorbilidades, la técnica quirúrgica, el IMC inicial y el porcentaje de exceso de IMC perdido (%EIMCP) al 6.°, 12.° y 24.° mes postoperatorio. Resultados: De los 415 pacientes intervenidos de CB, 280 han sido estudiados ya que no estaban colecistectomizados previamente y tenían una ecografía preoperatoria negativa para colelitiasis. Veintinueve desarrollaron CLNS (10,35%), con un aumento en la incidencia acumulada notablemente más alto durante el primer año postoperatorio (5%, IC 95% 2,4-7,6). Un mayor porcentaje de exceso de IMC perdido al 6.°, 12.° y 24.° mes postoperatorio se correlacionó de forma estadísticamente significativa con un mayor riesgo de CLNS. Conclusiones: La incidencia de CLNS y colecistectomía tras CB es relativamente alta, principalmente durante el periodo de pérdida de peso rápida, y más cuanto mayor sea el porcentaje de exceso de IMC perdido. La colecistectomía concomitante en caso de colelitiasis preoperatoria, independientemente de la sintomatología y el uso de ácido ursodesoxicólico durante el periodo de mayor riesgo para el desarrollo de CLNS, son dos opciones terapéuticas a tener en cuenta. (AU)


Introduction: Obesity and rapid weight loss after bariatric surgery (BS) are risk factors for the development of cholelitiasis. The aim of this study is to know the incidence of the de novo symptomatic cholelitiasis (DNSC) after BS and to analyze the risk factors for its development. Methods: Single-centre retrospective observational study of patients undergoing BS between January 2010 and December 2017. The incidence of DNSC has been studied and sex, age, comorbilities, surgical tecnique, initial BMI and percentage of excess BMI lost (%EIMCP) at 6th, 12th and 24th postoperative months have been analyzed. Results: Among the 415 patients who underwent BS, 280 have been studied since they were not previously cholecystectomized and had a preoperative negative abdominal ultrasound. Twenty-nine developed DNSC (10.35%), with a remarkably higher increase in cumulative incidence during the first postoperative year (5%, 95% CI 2,4-7,6). A higher percentage of excess BMI lost at the 6, 12 and 24 postoperative months was statistically significantly correlated with an increased risk of DNSC. Conclusions: Incidence of DNSC and cholecystectomy after BS are relatively high, mainly during rapid weight loss period and even more the higher the percentage of excess BMI lost is. Concomitant cholecystectomy during BS in case of preoperative cholelithiasis regardless of symptoms and the use of ursodeoxycholic acid during the period of greater risk for DNSC development are two therapeutic options to consider. (AU)


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Cirurgia Bariátrica , Colelitíase , Obesidade , Estudos Retrospectivos , Fatores de Risco , Ácido Ursodesoxicólico
11.
Cir Esp (Engl Ed) ; 99(9): 648-654, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34635453

RESUMO

INTRODUCTION: Obesity and rapid weight loss after bariatric surgery (BS) are risk factors for the development of cholelitiasis. The aim of this study is to know the incidence of the de novo symptomatic cholelitiasis (DNSC) after BS and to analyze the risk factors for its development. METHODS: Single-centre retrospective observational study of patients undergoing BS between January 2010 and December 2017. The incidence of DNSC has been studied and sex, age, comorbilities, surgical tecnique, initial BMI and percentage of excess BMI lost (%EBMIL) at 6th, 12th and 24th postoperative months have been analyzed. RESULTS: Among the 415 patients who underwent BS, 280 have been studied since they were not previously cholecystectomized and had a preoperative negative abdominal ultrasound. Twenty-nine developed DNSC (10,35%), with a remarkably higher increase in cumulative incidence during the first postoperative year (CI 5%, IC 95% 2,4-7,6). A higher percentage of excess BMI lost at the 6, 12 and 24 postoperative months was statistically significantly correlated with an increased risk of DNSC. CONCLUSIONS: Incidence of DNSC and cholecystectomy after BS are relatively high, mainly during rapid weight loss period and even more the higher the percentage of excess BMI lost is. Concomitant cholecystectomy during BS in case of preoperative cholelithiasis regardless of symptoms and the use of ursodeoxycholic acid during the period of greater risk for DNSC development are two therapeutic options to consider.


Assuntos
Cirurgia Bariátrica , Colelitíase , Obesidade Mórbida , Cirurgia Bariátrica/efeitos adversos , Colelitíase/epidemiologia , Humanos , Incidência , Fatores de Risco
12.
Cir Esp (Engl Ed) ; 2021 Sep 02.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-34482903

RESUMO

OBJECTIVE: Most evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma. METHOD: Multicentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS). RESULTS: A total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse. including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed. CONCLUSION: The present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients.

17.
Cir. Esp. (Ed. impr.) ; 99(3): 183-189, mar. 2021. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-217916

RESUMO

Introducción: El procedimiento LIFT para las FA de localización posterior ha sido cuestionado. Sin embargo esta controversia no ha sido analizada previamente y es el objetivo de esta revisión sistemática con metaanálisis. Material y método: Revisión sistemática PRISMA, de las bases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, Cochrane Library y Google Scholar hasta marzo de 2020. La evaluación de la calidad y sesgos de los estudios seleccionados se ha realizado mediante la escala Newcastle-Ottawa, según la AHRQ. Se empleó el método inverso de la varianza y el modelo de efectos aleatorios. Además, se realizó un análisis de sensibilidad y sobre el sesgo de publicación mediante funnel-plot y las pruebas de Beg y Egger. Resultados: No se apreciaron diferencias significativas en el porcentaje de recurrencias entre los pacientes con fístula posterior y el resto de localizaciones (OR 1,36 [IC 95% 0,60-3,07]; p=0,46). El valor I2 fue de 77%, lo cual muestra la heterogeneidad de resultados entre los estudios elegidos. Los 9 estudios incluidos presentaron una mediana ponderada (RI) de recidiva global del 37,8% (RI 18,3-47,7%), recidiva de fístula posterior del 47,1% (RI 30,7-63,7%) y de fístula no posterior del 36,3% (RI 15,8-51,3%) (p=0,436). Ni el número de pacientes ni la diferente calidad metodológica de los estudios explican el nivel de heterogeneidad de los mismos. No se demostró sesgo de publicación. (AU)


Introduction: Efficacy of the ligation of intersphincteric fistula tract (LIFT) procedure for posterior fistula-in-ano remains under debate. However, there is scarcity of quality evidence analysing this issue. Thus, the aim of this study is to evaluate outcomes of LIFT surgery in patients with posterior anal fistula. Material and methods: Systematic review and meta-analysis to evaluate efficacy of LIFT procedure for posterior anal fistula. MEDLINE (PubMed), EMBASE, Scopus, Web of Science, Cochrane Library and Google Scholar data sources were searched for key-words (MeSH terms): “LIFT” OR “Ligation of the intersphincteric fistula tract” AND “posterior anal fistula” OR “posterior fistula-in-ano”. Original, observational and experimental, non-language restriction studies published from January 2000 to March 2020 and reporting outcomes on LIFT procedure for posterior anal fistula were reviewed. Quality and potential biases were assessed using Newcastle-Ottawa scale, following AHRQ recommendations. Additional sensitivity analysis and publication bias evaluation (Beg and Egger's tets) were performed. Results: No significant differences were found in recurrence rate among patients undergoing LIFT procedure for posterior fistula-in-ano in contrast to other locations (OR 1.36 [IC 95% 0.60-3.07]; p=.46). I2 test value was 77%, expressing a fair heterogeneity among included studies. The weighed median for overall recurrence was 37.8% (RI 18.3-47.7%); with a weighed median of 47.1% (RI 30.7 - 63.7%) and 36.3% (RI 15.8-51.3%) (p=.436) respectively for recurrence after LIFT for posterior fistula and fistula in other locations. There was not clear evidence about the sample size (“n”) of included studies nor the disparities in quality assessment of those, could justify the observed heterogeneity. No significant publication bias was found. (AU)


Assuntos
Humanos , Fístula Retal/prevenção & controle , Fístula Retal/cirurgia , Viés de Publicação , MEDLINE , PubMed
18.
Cir. Esp. (Ed. impr.) ; 99(2): 89-107, feb. 2021. graf, tab
Artigo em Inglês | IBECS | ID: ibc-201223

RESUMO

Local excision (LE) has arisen as an alternative to total mesorectal excision for the treatment of early rectal cancer. Despite a decreased morbidity, there are still concerns about LE outcomes. This systematic-review and meta-analysis design is based on the "PICO" process, aiming to answer to three questions related to LE as primary treatment for early-rectal cancer, the optimal method for LE, and the potential role for completion treatment in high-risk histology tumors and outcomes of salvage surgery. The results revealed that reported overall survival (OS) and disease-specific survival (DSS) were 71%-91.7% and 80%-94% for LE, in contrast to 92.3%-94.3% and 94.4%-97% for radical surgery. Additional analysis of National Database studies revealed lower OS with LE (HR: 1.26; 95%CI, 1.09-1.45) and DSS (HR: 1.19; 95%CI, 1.01-1.41) after LE. Furthermore, patients receiving LE were significantly more prone develop local recurrence (RR: 3.44, 95%CI, 2.50-4.74). Analysis of available transanal surgical platforms was performed, finding no significant differences among them but reduced local recurrence compared to traditional transanal LE (OR:0.24;95%CI, 0.15-0.4). Finally, we found poor survival outcomes for patients undergoing salvage surgery, favoring completion treatment (chemoradiotherapy or surgery) when high-risk histology is present. In conclusion, LE could be considered adequate provided a full-thickness specimen can be achieved that the patient is informed about risk for potential requirement of completion treatment. Early-rectal cancer cases should be discussed in a multidisciplinary team, and patient's preferences must be considered in the decision-making process


La escisión local (EL) se ha planteado como una alternativa a la escisión mesorrectal total en el tratamiento del cáncer de recto inicial. A pesar de la reducción de la morbilidad, los resultados de la EL todavía son motivo de preocupación. Esta revisión sistemática y metaanálisis se basa en el proceso «PICO» con el objetivo de responder a tres preguntas relacionadas con la EL, a saber, como tratamiento principal del cáncer de recto inicial, el método óptimo de EL y su posible papel en el tratamiento completo de tumores histológicos de alto riesgo y complicaciones de la cirugía de rescate. Los resultados han puesto de manifiesto que la supervivencia general (SG) y la supervivencia específica por enfermedad (SEE) notificadas fueron del 71-91% y del 80-94% en el caso de la EL, en comparación con el 92,3-94,3% y el 94,4-97% en el caso de la cirugía radical, respectivamente. Un análisis complementario de los estudios de la Base de Datos Nacional reveló una SG (HR: 1,26; IC95%: 1,09-1,45) y una SEE inferiores (HR: 1,19; IC95%: 1,01-1,41) después de EL. Además, los pacientes que aceptaron la EL fueron mucho más propensos a presentar una recidiva local (RR: 3,44; IC95%: 2,50-4,74). Se llevó a cabo un análisis de los planteamientos quirúrgicos transanales disponibles. No se encontraron importantes diferencias entre ellos, pero las recidivas locales eran inferiores en comparación con las de la EL transanal tradicional (OR: 0,24; IC95%: 0,15-0,4). Por último, hubo malos resultados de supervivencia entre los pacientes a quienes se les realizó cirugía de rescate, lo que favorece el tratamiento completo (quimiorradioterapia o cirugía) cuando hay histología de alto riesgo. En conclusión, la EL podría considerarse adecuada siempre que se pueda lograr una muestra de espesor completo y el paciente esté informado del riesgo de una posible necesidad de tratamiento completo. Los casos de cáncer de recto inicial deben tratarse en un equipo multidisciplinario y las preferencias del paciente deben tenerse en cuenta en el proceso de toma de decisiones


Assuntos
Humanos , Masculino , Feminino , Neoplasias Retais/terapia , Tomada de Decisão Clínica/métodos , Árvores de Decisões , Viés , Prevenção Secundária , Resultado do Tratamento , Neoplasias Retais/mortalidade
19.
Eur J Surg Oncol ; 47(2): 276-284, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-32950316

RESUMO

INTRODUCTION: Preoperative treatment and adequate surgery increase local control in rectal cancer. However, modalities and indications for neoadjuvant treatment may be controversial. Aim of this study was to assess the trends of preoperative treatment and outcomes in patients with rectal cancer included in the Rectal Cancer Registry of the Spanish Associations of Surgeons. METHOD: This is a STROBE-compliant retrospective analysis of a prospective database. All patients operated on with curative intention included in the Rectal Cancer Registry were included. Analyses were performed to compare the use of neoadjuvant/adjuvant treatment in three timeframes: I)2006-2009; II)2010-2013; III)2014-2017. Survival analyses were run for 3-year survival in timeframes I-II. RESULTS: Out of 14,391 patients,8871 (61.6%) received neoadjuvant treatment. Long-course chemo/radiotherapy was the most used approach (79.9%), followed by short-course radiotherapy ±â€¯chemotherapy (7.6%). The use of neoadjuvant treatment for cancer of the upper third (15-11 cm) increased over time (31.5%vs 34.5%vs 38.6%,p = 0.0018). The complete regression rate slightly increased over time (15.6% vs 16% vs 18.5%; p = 0.0093); the proportion of patients with involved circumferential resection margins (CRM) went down from 8.2% to 7.3%and 5.5% (p = 0.0004). Neoadjuvant treatment significantly decreased positive CRM in lower third tumors (OR 0.71, 0.59-0.87, Cochrane-Mantel-Haenszel P = 0.0008). Most ypN0 patients also received adjuvant therapy. In MR-defined stage III patients, preoperative treatment was associated with significantly longer local-recurrence-free survival (p < 0.0001), and cancer-specific survival (p < 0.0001). The survival benefit was smaller in upper third cancers. CONCLUSION: There was an increasing trend and a potential overuse of neoadjuvant treatment in cancer of the upper rectum. Most ypN0 patients received postoperative treatment. Involvement of CRM in lower third tumors was reduced after neoadjuvant treatment. Stage III and MRcN + benefited the most.


Assuntos
Previsões , Margens de Excisão , Estadiamento de Neoplasias , Neoplasias Retais/terapia , Sistema de Registros , Adulto , Idoso , Idoso de 80 Anos ou mais , Quimiorradioterapia Adjuvante , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante , Neoplasias Retais/diagnóstico , Neoplasias Retais/epidemiologia , Estudos Retrospectivos , Espanha/epidemiologia , Taxa de Sobrevida/tendências , Resultado do Tratamento , Adulto Jovem
20.
Cir Esp (Engl Ed) ; 99(2): 89-107, 2021 Feb.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-32993858

RESUMO

Local excision (LE) has arisen as an alternative to total mesorectal excision for the treatment of early rectal cancer. Despite a decreased morbidity, there are still concerns about LE outcomes. This systematic-review and meta-analysis design is based on the "PICO" process, aiming to answer to three questions related to LE as primary treatment for early-rectal cancer, the optimal method for LE, and the potential role for completion treatment in high-risk histology tumors and outcomes of salvage surgery. The results revealed that reported overall survival (OS) and disease-specific survival (DSS) were 71%-91.7% and 80%-94% for LE, in contrast to 92.3%-94.3% and 94.4%-97% for radical surgery. Additional analysis of National Database studies revealed lower OS with LE (HR: 1.26; 95%CI, 1.09-1.45) and DSS (HR: 1.19; 95%CI, 1.01-1.41) after LE. Furthermore, patients receiving LE were significantly more prone develop local recurrence (RR: 3.44, 95%CI, 2.50-4.74). Analysis of available transanal surgical platforms was performed, finding no significant differences among them but reduced local recurrence compared to traditional transanal LE (OR:0.24;95%CI, 0.15-0.4). Finally, we found poor survival outcomes for patients undergoing salvage surgery, favoring completion treatment (chemoradiotherapy or surgery) when high-risk histology is present. In conclusion, LE could be considered adequate provided a full-thickness specimen can be achieved that the patient is informed about risk for potential requirement of completion treatment. Early-rectal cancer cases should be discussed in a multidisciplinary team, and patient's preferences must be considered in the decision-making process.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...